Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (158 pages)

Edition: 1st ed.

ISBN: 0-443-23882-0

Note: Front Cover -- Metabolomics of Bladder Cancer -- Metabolomics of Bladder Cancer An Emerging Application -- Copyright -- Contents -- Contributors -- 1 - Contribution of metabolomics in the discovery of biomarker for urinary bladder cancer -- Introduction -- Metabolomics techniques -- LC MS-based metabolomic analysis of human bladder cancer -- Selectivity and sensitivity -- Sample preparation -- Data analysis -- Example -- Multivariate statistical analysis -- NMR-based metabolomics analysis of human bladder cancer -- Sample preparations -- Multivariate pattern recognition and statistical analysis -- Conclusion -- References -- 2 - Role of tobacco on bladder cancer pathways -- Introduction -- Tobacco -- Tobacco products and bladder cancer -- Tobacco smoking -- Second hand smoke -- Smokeless tobacco -- Carcinogenic components of tobacco -- Polycyclic aromatic hydrocarbons -- Nitrosamines -- Aldehydes -- Others -- Bladder cancer pathways -- Tobacco smoke and aberrant methylation -- Tobacco smoke causes DNA damage and adducts -- Nitrosomine-induced bladder cancer -- Tobacco smoke causes epithelial-mesenchymal transition -- JNK pathway -- Ras pathway -- PI3K-AKT/mTOR pathway -- Wnt/β-catenin signaling pathway -- p53 and cell cycle -- Chemoresistance -- Smoking cessation -- Concluding remark and future challenges -- Abbreviations -- References -- 3 - Regulation of glycolysis in bladder cancer -- Introduction -- Role of different glycolytic pathway genes and enzymes in the progression of urinary bladder cancer -- Different strategies to control the regulation of glycolysis in urinary bladder cancer -- A key point of regulation in urinary bladder cancer metabolism is pkm2 -- PKM2 citrullination controls glycolysis and the growth of cancer cells in UBC. , Through the coactivation of hypoxia-inducible factor 1α, steroid receptor coactivator-3 controls glucose metabolism in blad ... -- Through the PTEN/PI3K/AKT/mTOR axis, a lentiviral sponge for miRNA-21 reduces aerobic glycolysis in bladder cancer -- Effects of Licochalcone A on the regulation of glycolysis in urinary bladder cancer -- Regulation of glycolysis by the long noncoding RNAs in urinary bladder cancer -- Regulation of glycolysis in bladder cancer by the knockdown of YBX1 factor -- Regulation of glycolysis via managing the expression of lysine deacetylase Sirtuin 1 in urinary bladder cancer -- In bladder cancer, orphan retinoic acid-related receptor C controls glycolysis through the pd-l1/itgb6/stat3 signaling axis -- Targeting various enzymes of glycolytic pathways with the inhibitors for the regulation of glycolysis in bladder cancer -- Through LDHA-dependent glycolysis reprogramming, CDKN3 reverses cisplatin resistance in bladder cancer -- Melatonin reduces the growth of bladder tumors by inhibiting PPAR/ENO1-mediated glycolysis -- Conclusion -- References -- 4 - Metabolism of fatty acid -- Introduction -- Metabolomics and biomarkers -- Fatty acids -- Fatty acids synthesis and oxidation -- Fatty acid oxidation/β-oxidation -- Pathways impacted by altered lipid metabolism in bladder cancer -- Fatty acid-based biomarkers for bladder cancer -- Implications for clinical management -- Future paths and significance of fatty acid metabolomics -- Early and accurate diagnosis -- Personalized treatment strategies -- Therapeutic monitoring and response assessment -- Identification of novel drug targets -- Understanding disease progression and prognosis -- Facilitating research and clinical trials -- Long-term implications for public health -- Preventive interventions -- Population health surveillance -- Precision public health. , Early detection and screening programs -- Data-driven policy making -- Research and development -- Health education and awareness -- Conclusion -- References -- 5 - Regulation of pentose phosphate pathway in bladder cancer -- Introduction -- Altered metabolism in malignant transformed cells -- Changes in glucose metabolism -- Crosslinks of glucose metabolism with pentose phosphate pathway -- Modifications in pentose phosphate pathway -- G6PDH -- 6PGDH -- RPI and RPE -- TALDO and TKT -- p53 -- Myc -- HIF-α -- The involvement of PPP in urothelial carcinoma cell survival -- Future implications: Application in treatment therapy -- Conclusion -- References -- 6 - Mitochondrial metabolism -- Introduction -- Mitochondria: The cellular powerhouses -- Structure and function of mitochondria -- Mitochondrial metabolism beyond energy production -- Carbohydrate metabolism -- Fatty acid metabolism -- Amino acid metabolism -- Mitochondria in cellular processes -- Mitochondrial DNA (mtDNA) and genetic variation -- Metabolic reprogramming in bladder cancer: Shifting the balance between glycolysis and oxidative phosphorylation -- Glycolysis versus oxidative phosphorylation -- Mitochondrial metabolic pathways in cancer -- Warburg effect in bladder cancer -- Mitochondrial metabolism in bladder cancer: Insights into altered dynamics, tumor progression, and energy balance -- Altered mitochondrial dynamics in cancer cells -- Impact of mitochondrial dysfunction on tumor progression -- The role of mitochondria in tumor energy balance -- Molecular mechanisms of mitochondrial dysfunction in bladder cancer -- Reactive oxygen species and oxidative stress -- Genetic and epigenetic factors -- Mitochondrial DNA mutations -- Cell proliferation and cell death -- Therapeutic targeting of mitochondrial metabolism in bladder cancer -- Targeting mitochondrial respiration. , Inhibiting complex I -- Targeting complex II -- Mitochondrial uncouplers -- Modulating mitochondrial dynamics -- Targeting Drp1 -- Promoting fusion -- Revitalizing mitochondria-driven apoptosis: Mitochondria-targeted therapies -- Challenges and future directions in targeting mitochondrial metabolism in bladder cancer -- Overcoming therapeutic challenges -- Ethical considerations -- Emerging technologies and research frontiers -- Conclusion: The promise of mitochondrial metabolism targeting in bladder cancer -- References -- 7 - Metabolic effect of cancer therapy -- Introduction -- Cancer metabolism -- Impact of cancer therapy on metabolism -- Impact of chemotherapy on metabolism -- Metabolic consequences of radiation therapy -- Immunotherapy and metabolic remodeling -- Metabolic reprogramming in cancer -- Metabolism as a therapeutic target -- Targeting metabolic vulnerabilities -- Combination therapies -- Metabolic challenges and opportunities in cancer therapy -- Metabolic heterogeneity and resistance -- Metabolic side effects and toxicities -- Metabolic imaging in cancer therapy -- Personalized cancer treatment based on metabolism -- Conclusion -- Future directions -- References -- 8 - Metabolomics and racial disparities in bladder cancer carcinogenesis -- Introduction -- Urothelial carcinoma of bladder: Two distinct entities -- Racial disparities on cancer incidence, risk factors, and survival -- Metabolomics: A new perspective -- Metabolomics in carcinogenesis -- Integrating racial disparities -- Metabolomic disparities in various racial and ethnic groups -- Challenges associated with bladder cancer management -- Research to clinical implications -- Recent developments/Future implications -- Multiomics: A bigger and a better picture -- References -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- L -- M -- N -- O -- P -- R -- S -- T. , U -- W -- Y -- Back Cover.

Additional Edition: ISBN 0-443-23881-2

Language: English